Pulse Biosciences Inc (PLSE)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $3.71B
Last updated: Nov 17, 2026 at 4:33 PM ET
Pulse Biosciences Inc (PLSE) Statistics
Pulse Biosciences (PLSE) has a market cap of $3.71B and an enterprise value of $3.67B. It kept -5603.88% of revenue as net income over the last 12 months. Its share count is up 6.74% from a year earlier.
Total Valuation
Enterprise value is 0.99% below the market cap, as cash exceeds debt.
| Market Cap | $3.71B |
|---|---|
| Enterprise Value | $3.67B |
| Latest price (Nov 17, 2026) | $44.84 |
Key Dates
The next earnings report is expected on Feb 17, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 17, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| P/B Ratio | 17.6x |
|---|---|
| P/TBV Ratio | 17.8x |
Price Statistics
The stock is up 211.39% over 52 weeks and trades 13.17% below its 50-day average.
| Beta (1Y) | 2.09 |
|---|---|
| 52-Week Change | +211.39% |
| 1-Month Change | -5.70% |
| 3-Month Change | -4.64% |
| 6-Month Change | +79.72% |
| 5-Year Change | +147.70% |
| 10-Year Change | +753.59% |
| Total Return (1Y) | +211.39% |
| Total Return (3Y CAGR) | +94.20% |
| Total Return (5Y CAGR) | +16.98% |
| Return vs SPY (1Y) | +218.63% |
| Max Drawdown (1Y) | -29.50% |
| Max Drawdown (3Y) | -48.45% |
| Sharpe Ratio (1Y) | 1.43 |
| Correlation with SPY (1Y) | 0.34 |
| 50-Day Average | $51.64 |
| 200-Day Average | $33.66 |
| 52-Week Range | $12.56 to $58.94 |
| RSI (14 Days) | 38.4 |
| Average Volume (20 Days) | 422.25K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 14.35x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 14.35x |
|---|---|
| Quick Ratio | 14.33x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -45.61% and return on assets is -41.53% over the last 12 months.
| Return on Equity (ROE) | -45.61% |
|---|---|
| Return on Assets (ROA) | -41.53% |
| ROA (5Y Average) | -74.31% |
| ROIC (5Y Average) | -73.72% |
| Asset Turnover | 0.01x |
| Inventory Turnover | 4.68x |
| Receivables Turnover | 7.13x |
| Cash Conversion Cycle | -847 days |
Scores
PLSE has an Altman Z-Score of 103.42, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 103.42 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $1.49M over the last 12 months is down 14.63% from the 12 months before.
| Revenue | $1.49M |
|---|---|
| Revenue Growth (YoY) | -14.63% |
| Gross Profit | $400.00K |
| Operating Income | -$86.97M |
| Pretax Income | -$83.72M |
| Net Income | -$83.72M |
| Reported EPS (TTM) | -$1.10 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 91.07% of the $201.58M in total assets.
| Cash and Equivalents | $36.73M |
|---|---|
| Total Debt | $0 |
| Net Cash | $36.73M |
| Net Cash Per Share | $0.51 |
| Working Capital | $178.81M |
| Shareholder Equity | $183.57M |
| Book Value Per Share | $2.55 |
| Tangible Book Value | $180.73M |
| Tangible Book Per Share | $2.51 |
| Total Assets | $201.58M |
| Total Liabilities | $18.01M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $370.00K of capital spending, operating cash flow left -$63.70M of free cash flow.
| Operating Cash Flow | -$63.33M |
|---|---|
| Capital Expenditures | $370.00K |
| Free Cash Flow | -$63.70M |
| FCF Per Share | -$0.89 |
| Depreciation and Amortization | $899.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -5821.08%.
| Gross Margin | 26.77% |
|---|---|
| Operating Margin | -5821.08% |
| Pretax Margin | -5603.88% |
| Net Margin | -5603.88% |
| FCF Margin | -4263.86% |
Growth
Revenue fell 20.63% a year over 3 years.
| Revenue Growth (3Y CAGR) | -20.63% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | +21.88% |
| Tangible Book Per Share Growth (2Y CAGR) | +26.14% |
Dividends and Yields
PLSE does not pay a dividend. Its free cash flow yield is -1.98%.
| FCF Yield | -1.98% |
|---|---|
| Buyback Yield | -4.45% |
| Shareholder Yield | -4.45% |
Analyst Forecast
Consensus estimates put revenue growth at 260.89% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +260.89% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About PLSE
What is PLSE's market cap?
Pulse Biosciences has a market cap of $3.71B. Its enterprise value, which adds debt and subtracts cash, is $3.67B.
How many shares of PLSE are outstanding?
Pulse Biosciences has 71.93M shares outstanding. The count is up 6.74% from a year earlier.
Does PLSE pay a dividend?
No. Pulse Biosciences does not pay a dividend.
How much debt does PLSE have?
Pulse Biosciences has $0 of total debt and $36.73M of cash and equivalents, a net cash position of $36.73M.
PLSE pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors